Can eculizumab be discontinued in aHUS?: Case report and review of the literature

BACKGROUND: The management of atypical hemolytic uremic syndrome (aHUS) has evolved into better control of thrombotic microangiopathy (TMA) and recovery of renal functions since the recent introduction of the terminal complement cascade blocker, eculizumab, into clinical use. Better characterization...

Descripción completa

Detalles Bibliográficos
Autores principales: Sahutoglu, Tuncay, Basturk, Taner, Sakaci, Tamer, Koc, Yener, Ahbap, Elbis, Sevinc, Mustafa, Kara, Ekrem, Akgol, Cuneyt, Caglayan, Feyza Bayraktar, Unsal, Abdulkadir, Daha, Mohamed R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
5200
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979790/
https://www.ncbi.nlm.nih.gov/pubmed/27495036
http://dx.doi.org/10.1097/MD.0000000000004330

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979790/
https://www.ncbi.nlm.nih.gov/pubmed/27495036
http://dx.doi.org/10.1097/MD.0000000000004330

Ejemplares similares